SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Proost, P. Articles by Van Damme, J. Search for Related Content PubMed PubMed Citation Articles by Proost, P. Articles by Van Damme, J. Related Collections Phagocytes Chemokines, Cytokines, and Interleukins Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2000, Vol. 96, No. 5, pp. 1674-1680 Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 into a most efficient monocyte attractant and CCR1 agonist Paul Proost, Patricia Menten, Sofie Struyf, Evemie Schutyser, Ingrid De Meester, and Jo Van Damme From the Laboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium, and the Department of Clinical Biochemistry, University of Antwerp, Wilrijk, Belgium. Chemokines are proinflammatory cytokines that play a role in leukocyte migration and activation. Recent reports showed that RANTES (regulated on activation normal T-cell expressed and secreted chemokine), eotaxin, macrophage-derived chemokine (MDC), and stromal cell-derived factor-1 (SDF-1) are NH2-terminally truncated by the lymphocyte surface glycoprotein and protease CD26/dipeptidyl peptidase IV (CD26/DPP IV). Removal of the NH2-terminal dipeptide resulted in impaired inflammatory properties of RANTES, eotaxin, MDC, and SDF-1. The potential CD26/DPP IV substrate macrophage inflammatory protein-1 (MIP-1) and the related chemokine, LD78 (ie, one of the MIP-1 isoforms), were not affected by this protease. However, CD26/DPP IV cleaved LD78, a most potent CCR5 binding chemokine and inhibitor of macrophage tropic human immunodeficiency virus-1 (HIV-1) infection, into LD78(3-70). Naturally truncated LD78(3-70), but not truncated MIP-1, was recovered as an abundant chemokine form from peripheral blood mononuclear cells. In contrast to all other chemokines processed by CD26/DPP IV, LD78(3-70) had increased chemotactic activity in comparison to intact LD78. With a minimal effective concentration of 30 pmol/L, LD78(3-70) became the most efficient monocyte chemoattractant. LD78(3-70) retained its high capacity to induce an intracellular calcium increase in CCR5-transfected cells. Moreover, on CCR1 transfectants, truncated LD78(3-70) was 30-fold more potent than intact LD78. Thus, CD26/DPP IV can exert not only a negative but also a positive feedback during inflammation by increasing the specific activity of LD78. CD26/DPP IV-cleaved LD78(3-70) is the most potent CCR1 and CCR5 agonist that retains strong anti-HIV-1 activity, indicating the importance of the chemokine-protease interaction in normal and pathologic conditions. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Savino, E. M. Borroni, N. M. Torres, P. Proost, S. Struyf, A. Mortier, A. Mantovani, M. Locati, and R. Bonecchi Recognition Versus Adaptive Up-regulation and Degradation of CC Chemokines by the Chemokine Decoy Receptor D6 Are Determined by Their N-terminal Sequence J. Biol. Chem., September 18, 2009; 284(38): 26207 - 26215. [Abstract] [Full Text] [PDF] S. Struyf, S. Noppen, T. Loos, A. Mortier, M. Gouwy, H. Verbeke, D. Huskens, S. Luangsay, M. Parmentier, K. Geboes, et al. Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4 J. Immunol., January 1, 2009; 182(1): 666 - 674. [Abstract] [Full Text] [PDF] C McKinney, M E Merriman, P T Chapman, P J Gow, A A Harrison, J Highton, P B B Jones, L McLean, J L O'Donnell, V Pokorny, et al. Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis Ann Rheum Dis, March 1, 2008; 67(3): 409 - 413. [Abstract] [Full Text] [PDF] P. Proost, A. Mortier, T. Loos, J. Vandercappellen, M. Gouwy, I. Ronsse, E. Schutyser, W. Put, M. Parmentier, S. Struyf, et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration Blood, July 1, 2007; 110(1): 37 - 44. [Abstract] [Full Text] [PDF] I Tikhonov, C. Deetz, R Paca, S Berg, V Lukyanenko, J. Lim, and C. Pauza Human V{gamma}2V{delta}2 T cells contain cytoplasmic RANTES Int. Immunol., August 1, 2006; 18(8): 1243 - 1251. [Abstract] [Full Text] [PDF] S. Meddows-Taylor, S. L. Donninger, M. Paximadis, D. B. Schramm, F. S. Anthony, G. E. Gray, L. Kuhn, and C. T. Tiemessen Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission J. Gen. Virol., July 1, 2006; 87(7): 2055 - 2065. [Abstract] [Full Text] [PDF] K. Ottersbach, J. Mclean, N. W. Isaacs, and G. J. Graham A310 helical turn is essential for the proliferation-inhibiting properties of macrophage inflammatory protein-1 alpha (CCL3) Blood, February 15, 2006; 107(4): 1284 - 1291. [Abstract] [Full Text] [PDF] J. K. Lim, J. M. Burns, W. Lu, and A. L. DeVico Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5 J. Leukoc. Biol., August 1, 2005; 78(2): 442 - 452. [Abstract] [Full Text] [PDF] R. D. Berahovich, Z. Miao, Y. Wang, B. Premack, M. C. Howard, and T. J. Schall Proteolytic Activation of Alternative CCR1 Ligands in Inflammation J. Immunol., June 1, 2005; 174(11): 7341 - 7351. [Abstract] [Full Text] [PDF] R. Colobran, P. Adreani, Y. Ashhab, A. Llano, J. A. Este, O. Dominguez, R. Pujol-Borrell, and M. Juan Multiple Products Derived from Two CCL4 Loci: High Incidence of a New Polymorphism in HIV+ Patients J. Immunol., May 1, 2005; 174(9): 5655 - 5664. [Abstract] [Full Text] [PDF] O. H. Ryu, S. J. Choi, E. Firatli, S. W. Choi, P. S. Hart, R.-F. Shen, G. Wang, W. W. Wu, and T. C. Hart Proteolysis of Macrophage Inflammatory Protein-1{alpha} Isoforms LD78{beta} and LD78{alpha} by Neutrophil-derived Serine Proteases J. Biol. Chem., April 29, 2005; 280(17): 17415 - 17421. [Abstract] [Full Text] [PDF] W. A. Weihofen, J. Liu, W. Reutter, W. Saenger, and H. Fan Crystal Structures of HIV-1 Tat-derived Nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) Bound to the Active Site of Dipeptidyl-peptidase IV (CD26) J. Biol. Chem., April 15, 2005; 280(15): 14911 - 14917. [Abstract] [Full Text] [PDF] E. Y. Tan, M. Mujoomdar, and J. Blay Adenosine Down-Regulates the Surface Expression of Dipeptidyl Peptidase IV on HT-29 Human Colorectal Carcinoma Cells: Implications for Cancer Cell Behavior Am. J. Pathol., July 1, 2004; 165(1): 319 - 330. [Abstract] [Full Text] [PDF] M. Strasly, G. Doronzo, P. Capello, D. Valdembri, M. Arese, S. Mitola, P. Moore, G. Alessandri, M. Giovarelli, and F. Bussolino CCL16 activates an angiogenic program in vascular endothelial cells Blood, January 1, 2004; 103(1): 40 - 49. [Abstract] [Full Text] [PDF] R. P. Gladue, L. A. Tylaska, W. H. Brissette, P. D. Lira, J. C. Kath, C. S. Poss, M. F. Brown, T. J. Paradis, M. J. Conklyn, K. T. Ogborne, et al. CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases J. Biol. Chem., October 17, 2003; 278(42): 40473 - 40480. [Abstract] [Full Text] [PDF] H.-C. Cheng, M. Abdel-Ghany, and B. U. Pauli A Novel Consensus Motif in Fibronectin Mediates Dipeptidyl Peptidase IV Adhesion and Metastasis J. Biol. Chem., June 27, 2003; 278(27): 24600 - 24607. [Abstract] [Full Text] [PDF] K. W. Christopherson II, S. Cooper, and H. E. Broxmeyer Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells Blood, June 15, 2003; 101(12): 4680 - 4686. [Abstract] [Full Text] [PDF] A.-C. Thierry, G. Perrenoud, S. Pinaud, N. Bigler, B. Denis, M. Roggero, C. Moulon, and S. Demotz Biotinylated Synthetic Chemokines: Their Use for the Development of Nonradioactive Whole-Cell Binding Assays J Biomol Screen, June 1, 2003; 8(3): 316 - 323. [Abstract] [PDF] K. W. Christopherson II, G. Hangoc, and H. E. Broxmeyer Cell Surface Peptidase CD26/Dipeptidylpeptidase IV Regulates CXCL12/Stromal Cell-Derived Factor-1{alpha}-Mediated Chemotaxis of Human Cord Blood CD34+ Progenitor Cells J. Immunol., December 15, 2002; 169(12): 7000 - 7008. [Abstract] [Full Text] [PDF] L. Agrawal, Z. Vanhorn-Ali, and G. Alkhatib Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs) J. Leukoc. Biol., November 1, 2002; 72(5): 1063 - 1074. [Abstract] [Full Text] [PDF] R. Geiben-Lynn, N. Brown, B. D. Walker, and A. D. Luster Purification of a Modified Form of Bovine Antithrombin III as an HIV-1 CD8+ T-cell Antiviral Factor J. Biol. Chem., October 25, 2002; 277(44): 42352 - 42357. [Abstract] [Full Text] [PDF] E. Guan, J. Wang, G. Roderiquez, and M. A. Norcross Natural Truncation of the Chemokine MIP-1beta /CCL4 Affects Receptor Specificity but Not Anti-HIV-1 Activity J. Biol. Chem., August 23, 2002; 277(35): 32348 - 32352. [Abstract] [Full Text] [PDF] A. Ludwig, F. Schiemann, R. Mentlein, B. Lindner, and E. Brandt Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine J. Leukoc. Biol., July 1, 2002; 72(1): 183 - 191. [Abstract] [Full Text] [PDF] T. Miyakawa, K. Obaru, K. Maeda, S. Harada, and H. Mitsuya Identification of Amino Acid Residues Critical for LD78beta , a Variant of Human Macrophage Inflammatory Protein-1alpha , Binding to CCR5 and Inhibition of R5 Human Immunodeficiency Virus Type 1 Replication J. Biol. Chem., February 8, 2002; 277(7): 4649 - 4655. [Abstract] [Full Text] [PDF] P. Proost, E. Schutyser, P. Menten, S. Struyf, A. Wuyts, G. Opdenakker, M. Detheux, M. Parmentier, C. Durinx, A.-M. Lambeir, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties Blood, December 15, 2001; 98(13): 3554 - 3561. [Abstract] [Full Text] [PDF] C. Blanpain, R. Buser, C. A. Power, M. Edgerton, C. Buchanan, M. Mack, G. Simmons, P. R. Clapham, M. Parmentier, and A. E. I. Proudfoot A chimeric MIP-1{alpha}/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors J. Leukoc. Biol., June 1, 2001; 69(6): 977 - 985. [Abstract] [Full Text] [PDF] S. Struyf, P. Proost, J.-P. Lenaerts, G. Stoops, A. Wuyts, and J. Van Damme Identification of a blood-derived chemoattractant for neutrophils and lymphocytes as a novel CC chemokine, Regakine-1 Blood, April 15, 2001; 97(8): 2197 - 2204. [Abstract] [Full Text] [PDF] A.-M. Lambeir, P. Proost, C. Durinx, G. Bal, K. Senten, K. Augustyns, S. Scharpe, J. Van Damme, and I. De Meester Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family J. Biol. Chem., August 3, 2001; 276(32): 29839 - 29845. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020